Buy or sell Evolve Biosystems stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Evolve Biosystems Stock
Evolve BioSystems is developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome.
About Evolve Biosystems Stock
Evolve Biosystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant biome and its intimate interaction with breast milk components established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004.
Investors
Bill & Melinda Gates Foundation
Apeel Sciences, Pivot Bio, Butterfly Network, Schrodinger, Evolve Biosystems, Heliogen
Funding History
| August 2015 | $9.0M |
|---|---|
| May 2017 | $20.0M |
| June 2018 | $40.0M |
Management
Director, IP & Regulatory Affairs
Samara Freeman
Co-Founder
Carlito Lebrilla
CEO
David Kyle
Co-Founder
Bruce German
Co-Founder
David Mills
Co-Founder
Daniela Barile
Press
Global University Venturing - Jun, 14 2018
PE Hub (blog) - Jun, 13 2018
PR Newswire (press release) - Dec, 6 2017
Marketwired (press release) - Aug, 1 2017
Marketwired (press release) - May, 30 2017
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
